UNSPSC 51341601: Somantadine

This classification denotes an antiviral agent with the molecular formula C14H25N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 02WMX1FS9Y chemically known as .alpha.,.alpha.-dimethyl-1-adamantaneethylamine but generally known as somantadine, which bears US NIH Compound Identifier 600809. European Medicines Agency schedules Somantadine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10580MIG.

UNSPSC 51341601 Somantadine is a Commodity code that appears in state and local procurement tied to pharmaceutical and medical supply sourcing, though recent opportunities show limited direct alignment with the somantadine compound itself. State and local governments are soliciting under this code framework for broader medical and pharmaceutical procurement — including naloxone and safe drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products, and medical first aid supplies for emergency response operations. The issuing bodies span multiple tiers: county health departments (Seminole County, Florida), city procurement bureaus (City of Tampa), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance). The geographic spread includes Florida, Texas, Minnesota, and Oregon, with activity across both large metropolitan jurisdictions and statewide/multi-state purchasing vehicles.

Recent representative opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2023, with quarterly deliveries to Sanford, Florida); the City of Tampa's sealed-bid solicitation for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, estimated at $700,000, with a 5 percent Small Local Business Enterprise set-aside and due March 13, 2026; the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026, effective July 1, 2026); and the Texas HHS Commission's RFI regarding a direct-to-manufacturer prescription program (due April 3, 2026). The code shows active procurement across supply-chain models ranging from traditional competitive bidding to cooperative purchasing and exploratory market research, with emphasis on pharmaceutical compliance, wholesaler relationships, and delivery logistics.